Month: September 2025

Kfar Saba, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the successful completion of a field trial of its DefendAir Stationary Turret system with Israel’s homeland security authority. The trial demonstrated the system’s effectiveness in securing critical infrastructure and sensitive facilities with comprehensive 360-degree perimeter protection, presenting a compelling investment opportunity. The trial was conducted in real-life conditions in Israel and tested the DefendAir turret configuration ability to hostile drones using an advanced optical detection and tracking subsystem. The system achieved 100% interception...

Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors FLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a supply agreement for Actinium-225 (Ac-225). The agreement will support the clinical development of Cellectar’s actinium-labeled phospholipid ether (PLE) radiopharmaceutical candidates, including its Phase 1-ready compound, CLR 121225, for the treatment of solid tumors. CLR 121225 (225Ac-CLR 121225), a novel actinium-labeled PLE, is under investigation...

WEST PALM BEACH, FL, Sept. 11, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (OTC: FOXO) (the “Company”), announces that it has signed a stock purchase agreement to acquire Vector Biosource Inc. (“Vector”). Vector is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector generated second quarter 2025 net revenues of approximately $225,000 ($0.9 million on an annual run rate basis) and is expected to grow significantly post-acquisition. The expected purchase price consists of: (i) $500,000 in cash, (ii) 60,000 shares of the Company’s Series E Cumulative Redeemable Secured Preferred Stock (the “Series E Preferred Stock”) ($1.5 million in stated value), (iii) warrants to purchase $2 million of the Company’s common stock at a 10% premium to...

According to Entrix, the project’s expansion is projected to boost the project’s revenue, potentially paving the way for higher returns to N2OFF’s stockholders. Neve Yarak, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) — N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, today announced its decision to extend additional debt financing to Solterra Renewable Energy Ltd. (“Solterra”) in connection with its previously reported Melz solar project for the purpose of integrating a large-scale battery energy storage system (BESS) into its 115 MWp solar photovoltaic project in Melz, Germany. The planned “green” BESS will have a capacity of 107 MW / 214 MWh and is designed to optimize electricity sales while providing additional grid services...

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $150.0 million, before deducting placement agent fees and other expenses. The private placement includes participation from both new and existing investors including Frazier Life Sciences, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, TCGX, and Venrock Healthcare Capital Partners, as well as other healthcare dedicated funds. The private placement will be for 4,000,002 shares of common stock...

SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced data from the Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis was accepted for a late-breaker oral presentation at the upcoming EADV Congress 2025, to be held in Paris, France from September 17-20, 2025. The Company will also present multiple poster presentations highlighting APG777’s best-in-class potential including data supporting its combination strategy. “These presentations highlighting our lead program, APG777, and earlier stage programs, underscore our commitment to bringing new treatment options that provide...

NEWARK, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, plans to announce its fiscal third quarter 2025 financial results after market close on Thursday, September 25, 2025. The Company also plans to host a conference call and webcast with the investment community to discuss the financial results that evening on Thursday, September 25, 2025, at 5:00 pm, Eastern Time. The live conference call webcast will be available in listen-only mode in the Investor Relations section of the Concentrix website under “Events and Presentations” at https://ir.concentrix.com/events-and-presentations A replay will also be available on the website following the conference call. About us: Powering a World That WorksConcentrix Corporation (NASDAQ: CNXC), a Fortune 500® company,...

MIAMI, Sept. 11, 2025 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) announced today that Barry S. Logan, Executive Vice President, is scheduled to present at the 13th Annual Morgan Stanley Laguna Conference being held at the Ritz Carlton, Laguna Niguel on Thursday, September 11, 2025 at 4:50 p.m. (PDT). Internet users can listen to a live webcast of the presentation at the Investor Relations section of Watsco’s website at http://www.watsco.com. About Watsco Watsco operates the largest distribution network for heating, air conditioning and refrigeration (HVAC/R) products with locations in the U.S., Canada, Mexico, and Puerto Rico, and on an export basis to Latin America and the Caribbean. Watsco estimates that over 375,000 contractors, technicians, and installers visit or call one of its 701 locations each year to get information,...

Leadership transition comes as the Company explores digital treasury strategies to complement its integrated energy model WOODS CROSS, Utah, Sept. 11, 2025 (GLOBE NEWSWIRE) — Sky Quarry Inc. (NASDAQ: SKYQ) (“Sky Quarry” or “the Company”), an integrated energy solutions company, today announced the appointment of Marcus Laun as Interim Chief Executive Officer. Mr. Laun, a co-founder of the Company with more than 25 years of capital markets experience, has held senior roles in finance and advised on digital asset initiatives such as tokenization and exchange development. As Interim CEO, he will guide Sky Quarry through its next stage of growth with a focus on sustainable operations and the advancement of a digital treasury strategy. These initiatives are intended to broaden potential sources of capital, expand...